Recent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impacting alternate pathways, and changes in the microenvironment. Here we review the role of these proteins in leukemogenesis, their respective inhibitors, mechanisms of resistance, and briefly ongoing studies aimed at overcoming resistance.
FLT3和IDH靶向抑制疗法的最新进展，显著提升了携带相应蛋白突变患者的缓解率与总生存期。尽管取得这些成效，耐药机制仍然不断出现，包括破坏抑制剂-靶点相互作用的突变、影响替代通路的突变以及微环境的变化。本文将综述这些蛋白在白血病发生中的作用、各自的抑制剂、耐药机制，并简要介绍当前旨在克服耐药性的研究进展。
肿瘤(癌症)患者之家